MicroRNA expression profiling and its clinical impact in breast cancer

MicroRNAs: Key Regulators of Oncogenesis

Volumn 9783319037257, Issue , 2014, Pages 355-367

  Ferracin, Manuela ^a   Lupini, Laura ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Breast cancer; Circulating microRNAs; Diagnosis; MicroRNA expression profiling; Prognosis; Therapy

Indexed keywords

EID: 84930448846     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-03725-7_14     Document Type: Chapter

References (69)

1. Adams BD, Furneaux H, White BA (2007) The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol 21(5):1132-1147.
2. Adams BD, Cowee DM, White BA (2009) The role of miR-206 in the epidermal growth factor (EGF) induced repression of estrogen receptor-alpha (ERalpha) signaling and a luminal phenotype in MCF-7 breast cancer cells. Mol Endocrinol 23(8):1215-1230.
3. Bhat-Nakshatri P, Wang G, Collins NR, Thomson MJ, Geistlinger TR, Carroll JS et al (2009) Estradiol-regulated microRNAs control estradiol response in breast cancer cells. Nucleic Acids Res 37(14):4850-4861.
4. Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ et al (2007) MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 8(10):R214.
5. Callegari E, Elamin BK, D'Abundo L, Falzoni S, Donvito G, Moshiri F et al (2013) Anti-tumor activity of a miR-199-dependent oncolytic adenovirus. PloS One 8(9):e73964.
6. Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, Sheldon H et al (2008) hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 14(5):1340-1348.
7. Castellano L, Giamas G, Jacob J, Coombes RC, Lucchesi W, Thiruchelvam P et al (2009) The estrogen receptor-alpha-induced microRNA signature regulates itself and its transcriptional response. Proc Natl Acad Sci U S A 106(37):15732-15737.
8. Chan M, Liaw CS, Ji SM, Tan HH, Wong CY, Thike AA et al (2013) Identification of circulating MicroRNA signatures for breast cancer detection. Clin Cancer Res 19(16):4477-4487.
9. Cookson VJ, Bentley MA, Hogan BV, Horgan K, Hayward BE, Hazelwood LD et al (2012) Circulating microRNA profiles reflect the presence of breast tumours but not the profiles of microRNAs within the tumours. Cell Oncol 35(4):301-308.
10. Cuk K, Zucknick M, Heil J, Madhavan D, Schott S, Turchinovich A et al (2013) Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer 132(7):1602-1612.
11. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ et al (2012) The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature 486(7403):346-352.
12. Di Leva G, Gasparini P, Piovan C, Ngankeu A, Garofalo M, Taccioli C et al (2010) MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J Natl Cancer Inst 102(10):706-721.
13. Dvinge H, Git A, Graf S, Salmon-Divon M, Curtis C, Sottoriva A et al (2013) The shaping and functional consequences of the microRNA landscape in breast cancer. Nature 497(7449):378-382.
14. Ferracin M, Calin GA (2011) Principles of MicroRNA involvement in breast cancer. Breast Dis Year Book Q 22(3):238-243.
15. Ferracin M, Pedriali M, Veronese A, Zagatti B, Gafa R, Magri E et al (2011) MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin. J Pathol 225(1):43-53.
16. Foekens JA, Sieuwerts AM, Smid M, Look MP, de Weerd V, Boersma AW et al (2008) Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci U S A 105(35):13021-13026.
17. Galea MH, Blamey RW, Elston CE, Ellis IO (1992) The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22(3):207-219.
18. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2009) Thresholds for therapies: Highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20(8):1319-1329.
19. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G et al (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10(5):593-601.
20. Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S et al (2008) The microRNAs miR- 373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 10(2):202-210.
21. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S et al (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65(16):7065-7070.
22. Iorio MV, Casalini P, Piovan C, Di Leva G, Merlo A, Triulzi T et al (2009) microRNA-205 regulates HER3 in human breast cancer. Cancer Res 69(6):2195-2200.
23. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A et al (2005) RAS is regulated by the let-7 microRNA family. Cell 120(5):635-647.
24. Koboldt DC, Fulton RF, McLellan MD, Schmidt M, Kalicki-Veizer J, TCGA N (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61-70.
25. Kondo N, Toyama T, Sugiura H, Fujii Y, Yamashita H (2008) miR-206 expression is down- regulated in estrogen receptor alpha-positive human breast cancer. Cancer Res 68(13):5004-5008.
26. Kong W, He L, Coppola M, Guo J, Esposito NN, Coppola D et al (2010) MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem 285(23):17869-17879.
27. Korpal M, Lee ES, Hu G, Kang Y (2008) The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 283(22):14910-14914.
28. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW et al (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137(6):1005-1017.
29. Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF et al (2008) Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 7(7):2152-2159.
30. Krichevsky AM, Gabriely G (2009) miR-21: A small multi-faceted RNA. J Cell Mol Med 13(1):39-53.
31. Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ et al (2007) A microRNA signature of hypoxia. Mol Cell Biol 27(5):1859-1867.
32. Le Quesne J, Caldas C (2010) Micro-RNAs and breast cancer. Mol Oncol 4(3):230-241.
33. Li H, Bian C, Liao L, Li J, Zhao RC (2011) miR-17-5p promotes human breast cancer cell migration and invasion through suppression of HBP1. Breast Cancer Res Treat 126(3):565-575.
34. Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C et al (2009) MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res 11(3):R27.
35. Lu Z, Liu M, Stribinskis V, Klinge CM, Ramos KS, Colburn NH et al (2008) MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 27(31): 4373-4379.
36. Ma L, Teruya-Feldstein J, Weinberg RA (2007) Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449(7163):682-688.
37. Ma L, Reinhardt F, Pan E, Soutschek J, Bhat B, Marcusson EG et al (2010) Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol 28(4):341-347.
38. Madhavan D, Cuk K, Burwinkel B, Yang R (2013) Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures. Front Genet 4:116.
39. Maillot G, Lacroix-Triki M, Pierredon S, Gratadou L, Schmidt S, Benes V et al (2009) Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth. Cancer Res 69(21):8332-8340.
40. Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, Dupont S et al (2010) A MicroRNA targeting dicer for metastasis control. Cell 141(7):1195-1207.
41. Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK et al (2006) Optimized highthroughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 5:24.
42. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL et al (2008) MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 283(44):29897-29903.
43. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105(30):10513-10518.
44. Pandey DP, Picard D (2009) miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor alpha mRNA. Mol Cell Biol 29(13):3783-3790.
45. Park SM, Gaur AB, Lengyel E, Peter ME (2008) The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 22(7):894-907.
46. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747-752.
47. Piovan C, Palmieri D, Di Leva G, Braccioli L, Casalini P, Nuovo G et al (2012) Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. Mol Oncol 6(4):458-472.
48. Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI, Kovalchuk O (2010) Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer 127(8):1785-1794.
49. Qi L, Bart J, Tan LP, Platteel I, Sluis T, Huitema S et al (2009) Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer 9:163.
50. Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R et al (2009) High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGFbeta1. Breast Cancer Res Treat 117(1):131-140.
51. Rodriguez-Gonzalez FG, Sieuwerts AM, Smid M, Look MP, Meijer-van Gelder ME, deWeerd V et al (2011) MicroRNA-30c expression level is an independent predictor of clinical benefi t of endocrine therapy in advanced estrogen receptor positive breast cancer. Breast Cancer Res Treat 127(1):43-51.
52. Salter KH, Acharya CR, Walters KS, Redman R, Anguiano A, Garman KS et al (2008) An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. PloS One 3(4):e1908.
53. Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC (2007) Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem 282(2):1479-1486.
54. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1): 10-29.
55. Spizzo R, Nicoloso MS, Lupini L, Lu Y, Fogarty J, Rossi S et al (2010) miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death Differ 17(2):246-254.
56. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD et al (2008) Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451(7175):147-152.
57. Tong AW, Nemunaitis J (2008) Modulation of miRNA activity in human cancer: A new paradigm for cancer gene therapy? Cancer Gene Ther 15(6):341-355.
58. Wickramasinghe NS, Manavalan TT, Dougherty SM, Riggs KA, Li Y, Klinge CM (2009) Estradiol down regulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. Nucleic Acids Res 37(8):2584-2595.
59. Xiong J, Yu D, Wei N, Fu H, Cai T, Huang Y et al (2010) An estrogen receptor alpha suppressor, microRNA-22, is down regulated in estrogen receptor alpha-positive human breast cancer cell lines and clinical samples. FEBS J 277(7):1684-1694.
60. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL et al (2008) MicroRNA miR-21 over expression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 14(11):2348-2360.
61. Yang N, Kaur S, Volinia S, Greshock J, Lassus H, Hasegawa K et al (2008) MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 68(24):10307-10314.
62. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C et al (2007) let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131(6):1109-1123.
63. Yu Z, Wang C, Wang M, Li Z, Casimiro MC, Liu M et al (2008) A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol 182(3):509-517.
64. Yu Z, Baserga R, Chen L, Wang C, Lisanti MP, Pestell RG (2010a) microRNA, cell cycle, and human breast cancer. Am J Pathol 176(3):1058-1064.
65. Yu Z, Willmarth NE, Zhou J, Katiyar S, Wang M, Liu Y et al (2010b) microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling. Proc Natl Acad Sci U S A 107(18):8231-8236.
66. Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X et al (2008) MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem 283(45):31079-31086.
67. Zhao Y, Deng C, Wang J, Xiao J, Gatalica Z, Recker RR et al (2011) Let-7 family miRNAs regulate estrogen receptor alpha signaling in estrogen receptor positive breast cancer. Breast Cancer Res Treat 127(1):69-80.
68. Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi Y et al (2010) MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem 285(28):21496-21507.
69. Zhu S, Wu H, Wu F, Nie D, Sheng S, Mo YY (2008) MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 18(3):350-359.